The demand for weight-loss drugs in the UK is rising, with Eli Lilly's (LLY, Financial) Mounjaro gaining popularity over Novo Nordisk's (NVO) Wegovy. Despite its 40% higher initial dose price, Mounjaro's superior weight-loss results have attracted significant consumer interest. Chemist4U's CEO noted Mounjaro now commands 70% of their weight-loss drug sales. Online estimates suggest up to 500,000 UK users are prescribed these drugs privately.
Mounjaro, unavailable through the NHS, might join next year, while Wegovy is only available in specialized clinics. Eli Lilly's Mounjaro, launched in the UK in February, is one of the few direct competitors to Novo Nordisk. Analysts predict the global weight-loss market could reach $150 billion annually in the next decade.
